About Us

Milestones

2005

Oct.

Company established

 

2006

Feb.

Set up R&D Lab in Taipei Medical University Incubation Center

2007

Jun.

Received government-sponsored SBIR grant to develop Gemcitabine oral dosage form

 

Aug.

Received ANDA approval for anti-bacteria drug "Bestnem®"and MRI contrast agent "Gadomni®" from Taiwan FDA

2008

Mar.

Licensed and-in and co-developed for Bendamustine with SymBio Pharmaceuticals

 

Sep.

Received "New Drug Development" endorsement from government MOEA

2009

May

Received ANDA approval for immuno-suppression drug "Immurin®"and MRI contrast agent "Gadoscan®" from Taiwan FDA

 

Jun.

Received ITDP Grant for Gemcitabine Oral Development

2011

Sep.

Received US FDA IND approval for Gemcitabine Hydrochloride Oral Formulation (D07001-F4)

 

Oct.

Received NDA approval for Bendamustine (Innomustine®) from Taiwan FDA

2012

Aug.

Signed distribution contract for MRI products with Akorn(NASDAQ listed company) for US market

 

Sep.

Listed on Emerging Stock Market in Taiwan Stock Exchange, the ticker symbol is 4172

2014

Apr.

Completed the PK clinical study of Gemcitabine Oral in USA

 

May.

Gadopentetate filed US ANDA through Akorn

2015

Jul.

Selected as a company of “BIO Taiwan Highlights 2015”by IBMI

 

Aug.

US FDA agreed the company’s Carvedilol CR Tablet will be eligible for NDA submission after BE study completion

 

Nov.

Completed Clinical Phase I Trial for Gemcitabine HCI Formulation

2016

Jan.

Received FDA Orphan Drug Designation for Gemcitabine in the Treatment of Cholangiocarcinoma

 

Apr.

Signed contract of distribution to Canada market defined Middle East countries for Gadomni®, Gadoscan®, Immurin® and other 2 MRI products with Avir Pharma

2017

Mar.

Signed product supply and distribution contract for Gadoscan® with Shenzhen Rosso Pharmaceutical Co. Ltd in China

 

Jul.

Signed distribution contract for Inpheno Tablets with BL&H Co. Ltd. for Korea Market

 

Aug.

InnoPharmax Received IND Approval from US FDA to Proceed with Clinical Development in Efficacy, Pharmacokinetics and Safety of Gemcitabine Oral Formulation in Biliary Tract Cancer

2018

Mar.

Signed license-out & supply contract for Inpheno with China New Age Pharmaceuitical Co., Ltd. For China & Spain market

 

Apr.

Signed license-out contract for Oral Insulin with HEC(1558.HK) for China market

 

Jul.

Filed Gadopentetate Dimeglumine injection ANDS to Health Canada through Avir Pharma

 

 

Awards

2009

Nov.

Won a Bronze award in the "Taiwan Healthcare Industry Innovation and Excellence Awards 2009"

2012

Sep.

Awarded "2012 Taipei Biotech Research and Development Innovation Golden Award"

 

Dec.

Gemcitabine OralPAS® was awarded the 9th National Innovation Award in the Innovative Technology Category

 

2013

Aug.

Awarded "2013 Excellence Award for Research and Development Results in the Technology Development Program of DoIT of MOEA"

2014

Jul.

Received "2014 Taiwan Bio Industry Organization Award"

2015

Dec.

Rank as 7th place in Taiwan on the selecting list of "Technology Fast 500™ Asia Pacific 2015" by Deloitte

 

 



優吉兒網站設計 - Website Info.